Page last updated: 2024-12-07

3-heptyl-4-hydroxy-7-methoxy-2-methylquinoline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-heptyl-4-hydroxy-7-methoxy-2-methylquinoline: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID100474
CHEMBL ID527822
MeSH IDM0188850

Synonyms (23)

Synonym
AKOS005449039
nsc305757
nsc-305757
4939-34-8
4-quinolinol, 3-heptyl-7-methoxy-2-methyl-
3-heptyl-7-methoxy-2-methyl-quinolin-4-ol
3-heptyl-7-methoxy-2-methylquinolin-4(1h)-one
STK377496
CHEMBL527822
3-heptyl-7-methoxy-2-methyl-1h-quinolin-4-one
TCMDC-137173 ,
nsc 305757
wr-7295
3-heptyl-4-hydroxy-7-methoxy-2-methylquinoline
wr 7295
endochin
DTXSID80197780
354155-51-4
3-heptyl-7-methoxy-2-methyl-4(1h)-quinolone
3-heptyl-7-methoxy-2-methyl-4-quinolinol
3-heptyl-7-methoxy-2-methylquinolin-4-ol
CS-0007963
HY-13833

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Many lead compounds fail to reach clinical trials despite being potent because of low bioavailability attributed to their insufficient solubility making solubility a primary and crucial factor in early phase drug discovery."( Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
Baidya, ATK; Das, B; Kumar, R; Mathew, AT; Yadav, AK, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID1140154Antimalarial activity against multidrug-resistant Plasmodium falciparum Dd2 MRA-156 infected in human red blood cells assessed as suppression of parasitemia after 72 hrs by SYBR Green I-based fluorescence method2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.
AID1140156Cytotoxicity against human HepG2 cells after 24 hrs incubation by Alamar Blue assay2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.
AID1140157Inhibition of human cytochrome bc1 complex derived from HEK293 cell mitochondria using 50 uM decylubiquinol as substrate2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.
AID517478Antimalarial activity against chloroquine, mefloquine, pyrimethamine and atovaquone-resistant Plasmodium falciparum TM90-C2B infected in human A+ erythrocytes after 72 hrs by SYBR Green I assay2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.
AID517483Aqueous solubility of the compound at pH 7.4 by HPLC analysis2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.
AID517488Half life in human liver microsomes2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.
AID1140153Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 MRA-285 infected in human red blood cells assessed as suppression of parasitemia after 72 hrs by SYBR Green I-based fluorescence method2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.
AID517481Cytotoxicity against mouse J774 cells2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.
AID1866020Thermodynamic aqueous solubility of the compound2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
AID517486Passive transcellular permeability of the compound at pH 4 by PAMPA2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.
AID517484Lipophilicity, log D of the compound at pH 7.42010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.
AID517482Cytotoxicity index, ratio of EC50 for mice (Mus musculus) J774 cells to EC50 for chloroquine, mefloquine, pyrimethamine and atovaquone-resistant Plasmodium falciparum TM90-C2B2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.
AID1160940Half life in mouse liver microsomes at 1 uM by LC-MS analysis2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.
AID517485Passive transcellular permeability of the compound at pH 7.4 by PAMPA2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.
AID1866086Antimalarial activity against blood stage multi drug-resistant Plasmodium falciparum W2 isolate2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
AID1140158Antimalarial activity against Plasmodium yoelii MR4 MRA-428 infected in mouse CF1 assessed as reduction on parasite burden administered through oral gavage once daily for 4 days2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.
AID517480Antimalarial activity against chloroquine and pyrimethamine-resistant Plasmodium falciparum W2 infected in human A+ erythrocytes after 72 hrs by SYBR Green I assay2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.
AID1140155Antimalarial activity against atovaquone-resistant clinical isolate Plasmodium falciparum TM90-C2B infected in human red blood cells assessed as suppression of parasitemia after 72 hrs by SYBR Green I-based fluorescence method2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.
AID1866021Lipophilicity, logD of compound2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
AID1140159Antimalarial activity against Plasmodium yoelii MR4 MRA-428 infected in mouse CF1 assessed as dose required to achieve cure measured as 30 days survival administered through oral gavage once daily for 4 days2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.
AID517479Resistant index. ratio of EC50 for chloroquine, mefloquine, pyrimethamine and atovaquone-resistant Plasmodium falciparum TM90-C2B to EC50 for chloroquine and pyrimethamine-resistant Plasmodium falciparum W22010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.
AID517487Half life in mouse liver microsomes2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.
AID1159587Biochemical screen of P. falciparum PK72016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159588Biochemical screen of P. falciparum CDPK42016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159589Biochemical screen of P. falciparum MAPK22016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159586Biochemical screen of P. falciparum PK62016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159585Biochemical screen of P. falciparum CDPK12016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.05 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]